Convergent Calling: An Interview with Medtronic's Stephen Oesterle

Historic walls between the medical device and biotech sectors are coming down as medical devices incorporate more biologically-active agents as part of their therapy. That's good news for device companies since device technology in these combination devices is every bit as critical to their clinical success as the biologic.

By David Cassak

For much of the 1990s, though they shared billing as life sciences or medical technology sectors, medical devices and biotechnology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo